Form D · Pharmaceuticals
RVL Pharmaceuticals plc
Bridgewater, NJ · CIK 0001739426
Offering snapshot reported Aug 31, 2023 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 18, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 31, 2023 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $813K
- Finders' fees
- $0
- Form D file number
- 021-491138
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. WAINWRIGHT & CO., LLC | 375 |
Source: Form D, filed Aug 31, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joaquin Benes | Director |
| Gregory Cowan | Director |
| Michael Debiasi | Director |
| Alisa Lask | Director |
| Brian Markison | Director, Executive |
| James Schaub | Executive |
| Juan Vergez | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
400 Crossing Boulevard
Bridgewater, NJ, 08807
Bridgewater, NJ, 08807